Gaucher Disease, Type 3

Also known as: Gaucher's disease type III / Gaucher Disease, Type III / Gaucher Disease Type 3 / Type 3 Gaucher disease / Subacute neuronopathic Gaucher's disease (disorder)

DrugDrug NameDrug Description
DB00053ImigluceraseA form of recombinant human beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease.
DB08876Taliglucerase alfaA hydrolytic lysosomal glucocerebroside specific enzyme, used for long term enzyme replacement therapy in patients with Type 1 Gaucher disease.
DrugDrug NamePhaseStatusCount
DB01272Alglucosidase alfa1Recruiting1
DB09051Elosulfase alfa1Recruiting1
DB01279Galsulfase1Recruiting1
DB01271Idursulfase1Recruiting1
DB00090Laronidase1Recruiting1
DB11563Sebelipase alfa1Recruiting1
DB12366Vestronidase alfa1Recruiting1
DB05543Velaglucerase alfa1 / 2Completed1
DB06720Velaglucerase alfa1 / 2Completed1
DB05025Arimoclomol2Terminated1
DB00053Imiglucerase2Active Not Recruiting1
DB14966Venglustat2Active Not Recruiting1
DB17650AVR-RD-022 / 3Withdrawn1
DB00053Imiglucerase2 / 3Withdrawn1
DB08876Taliglucerase alfa2 / 3Withdrawn1
DB09039Eliglustat3Active Not Recruiting1
DB00053Imiglucerase3Active Not Recruiting1
DB00053Imiglucerase3Recruiting1
DB14966Venglustat3Recruiting1
DB11105Benzalkonium4Completed1
DB08876Taliglucerase alfa4Completed1
DB06720Velaglucerase alfa4Withdrawn1
DB09039EliglustatNot AvailableCompleted1